PHARMARON (03759.HK) intends to hold a Board of Directors meeting on March 26 to approve the annual performance.

Gelonghui, March 12 | PHARMARON (03759.HK) announced that a Board of Directors meeting will be held on March 26, 2025 (Wednesday), to review and approve the performance of the company and its subsidiaries for the year ending December 31, 2024, and to consider the proposal for a final dividend (if any).

Gelonghui FinanceMar 12 05:04 ET

PHARMARON: NOTICE OF BOARD MEETING

HKEXMar 12 05:00 ET · Announcements

PHARMARON (300759.SZ) Shareholder announced that it has completed Shareholding, with a total reduction of 10.6667 million shares.

PHARMARON (300759.SZ) announced that the company received notification from Xinchongkangcheng and its concerted actor Shenzhen Xinchonglongcheng...

Zhitong FinanceMar 7 05:13 ET

National People's Congress representative, Zhao Jing of Shandong Buchang Pharmaceuticals: "The 'AI+' is reaching a critical point of explosion. It is recommended to utilize AI to empower the inheritance and innovation of Traditional Chinese Medicine | Two

① Zhao Jing, a representative of the National People's Congress and Vice Director of Shandong Buchang Pharmaceuticals, brought the proposal "Utilizing AI to Empower the Inheritance and Innovation of Traditional Chinese Medicine and Build a New Pattern of Development for Traditional Chinese Medicine with 'Asia Vets + Technology'" to this year's Two Sessions, aiming to promote the intelligent upgrade of the Traditional Chinese Medicine industry through AI technology. ② Zhao Jing stated that the development of large models like DeepSeek has indeed pushed the integration of Traditional Chinese Medicine and AI to a critical point of explosion.

cls.cnMar 6 20:48 ET

The investment secrets in the government work report: Analyzing the collaborative logic of the Global Strategy and policies of Guoshengtang (2273.HK).

The report clearly states to strengthen basic Medical and health services.

Gelonghui FinanceMar 5 20:15 ET

GTJA: AI technology drives efficiency innovation and optimizes the entire R&D chain of the CXO industry.

The penetration of AI technology accelerates the paradigm shift in the CXO industry. The deep application of AI technology in the Biomedical field is expected to reconstruct the value chain of the CXO industry.

Zhitong FinanceMar 5 03:29 ET